表紙
市場調査レポート

難治性急性骨髄性白血病:世界の治験レビュー

Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H2, 2016

発行 GlobalData 商品コード 299734
出版日 ページ情報 英文 384 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
難治性急性骨髄性白血病:世界の治験レビュー Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H2, 2016
出版日: 2016年07月29日 ページ情報: 英文 384 Pages
概要

当レポートでは、難治性急性骨髄性白血病の治療薬に関する治験について調査分析し、治験数および被験者数、段階別・相別の状況、有望企業、開発中の治療薬の情報、治験プロファイルなどを提供して、概略以下の構成でお届けいたします。

目次

イントロダクション

地域別の治験

  • 国別の治験動向
    • アジア太平洋地域の主要国
    • 欧州の主要国
    • 北米の主要国
    • 中東・アフリカの主要国
    • 中南米の主要国

G7諸国における治験:腫瘍科の治験に対する難治性急性骨髄性白血病の割合

G7諸国における治験:相別

G7諸国における治験:段階別

E7諸国における治験:腫瘍科の治験に対する難治性急性骨髄性白血病の割合

E7諸国における治験:相別

E7諸国における治験:段階別

相別の治験

段階別の治験

評価項目別の治験

未完了の治験

一定期間に採用された被験者

スポンサータイプ別の治験

有望なスポンサー

  • 難治性急性骨髄性白血病の治療薬の治験に参加している主要企業

有望薬

最新の治験ニュース

治験プロファイル

  • 主要企業の治験概要
    • Novartis AG
    • Pfizer Inc.
    • Celgene Corporation
    • Sanofi
    • C. H. Boehringer Sohn AG & Co. KG
    • Ambit Biosciences Corporation
    • F. Hoffmann-La Roche Ltd.
    • AROG Pharmaceuticals LLC
    • Amgen Inc.
    • AbbVie Inc.
  • 主要大学・研究機関・病院の治験概要
    • National Cancer Institute
    • Fred Hutchinson Cancer Research Center
    • Children's Oncology Group
    • The University of Texas M. D. Anderson Cancer Center
    • Stanford University
    • Washington University School of Medicine
    • Roswell Park Cancer Institute
    • Sidney Kimmel Comprehensive Cancer Center
    • Case Comprehensive Cancer Center

主な臨床プロファイル

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3631CTIDB

GlobalData's clinical trial report, "Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H2, 2016" provides an overview of Refractory Acute Myeloid Leukemia clinical trials scenario. This report provides top line data relating to the clinical trials on Refractory Acute Myeloid Leukemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials 28
  • Prominent Drugs 30
  • Latest Clinical Trials News on Refractory Acute Myeloid Leukemia 31
  • Jul 20, 2016: Actinium Pharmaceuticals Highlights Successful Investigator Meeting for Pivotal Phase 3 Iomab-B SIERRA Trial 31
  • Jul 06, 2016: Actinium Pharmaceuticals to Sponsor Investigator Meeting for Pivotal Phase 3 SIERRA Trial for Iomab-B 32
  • Jun 29, 2016: Actinium Pharmaceuticals Initiates Pivotal Phase 3 SIERRA Trial 33
  • Jun 13, 2016: Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Drug Combination Strategies Due to the Targeting of MCL-1 34
  • Jun 09, 2016: Actinium Announces Strong Presence at Society of Nuclear Medicine and Molecular Imaging Annual Meeting 34
  • Jun 06, 2016: GlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia 35
  • Jun 06, 2016: Tolero Pharmaceuticals To Present Update On Alvocidib Program At 2016 EHA Congress 36
  • Jun 06, 2016: Tolero Pharmaceuticals To Present Update On TP-1287 Program At 2016 EHA Congress 36
  • May 31, 2016: Syros Pharmaceuticals Announces FDA Acceptance of IND to Advance SY-1425 Into Phase 2 Clinical Trial 36
  • May 19, 2016: Astellas Oncology Announces Data on gilteritinib to be Presented at 2016 ASCO Annual Meeting 37
  • May 19, 2016: BioLineRx BL-8040 to be Presented at Upcoming Scientific Conferences 37
  • Clinical Trial Profile Snapshots 38

Appendix 381

  • Abbreviations 381
  • Definitions 381
  • Research Methodology 382
  • Secondary Research 382
  • About GlobalData 383
  • Contact Us 383
  • Disclaimer 383
  • Source 384

List of Tables

List of Tables

  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region, 2016* 6
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14
  • Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2016* 15
  • Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
  • Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
  • Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2016* 18
  • Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
  • Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase, 2016* 21
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
  • Refractory Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

List of Figures

List of Figures

  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14
  • Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2016* 15
  • Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
  • Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
  • Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2016* 18
  • Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
  • Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
  • Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
  • Refractory Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
  • Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30
  • GlobalData Methodology 382
Back to Top